Rapid-acting antidepressants targeting modulation of the glutamatergic system: clinical and preclinical evidence and mechanisms

Major depressive disorder (MDD) is a devastating mental illness that affects approximately 20% of the world’s population. It is a major disease that leads to disability and suicide, causing a severe burden among communities. Currently available medications for treating MDD target the monoaminergic s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shikai, Tang, Sufang, Huang, Jintao, Chen, Huanxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743367/
https://www.ncbi.nlm.nih.gov/pubmed/36605479
http://dx.doi.org/10.1136/gpsych-2022-100922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743367/
https://www.ncbi.nlm.nih.gov/pubmed/36605479
http://dx.doi.org/10.1136/gpsych-2022-100922

Ejemplares similares